{"id":524255,"date":"2021-08-05T10:33:10","date_gmt":"2021-08-05T14:33:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/"},"modified":"2021-08-05T10:33:10","modified_gmt":"2021-08-05T14:33:10","slug":"mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/","title":{"rendered":"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>MYMD-1 human cell research study demonstrates drug\u2019s ability to target immune dysfunction and cytokine storm that leads to death from COVID-19<\/i><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><i>Phase 2 trial of MYMD-1 as a therapy for COVID-19-associated depression and cytokine elevation expected to begin by fourth quarter 2021; initial trial data expected in first quarter 2022<\/i><\/li>\n<\/ul>\n<p>BALTIMORE, Md.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mymd.com%2F&amp;esheet=52472092&amp;newsitemid=20210805005659&amp;lan=en-US&amp;anchor=MyMD+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=d3ebbab3b6cb3d8e7a74ef72822209d4\">MyMD Pharmaceuticals, Inc.<\/a> (Nasdaq: MYMD) (\u201cMyMD\u201d or \u201cthe Company\u201d), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that a human cell research study of lead clinical compound MYMD-1 found the drug to be effective in suppressing the cytokine storm, a major cause of severity and death in COVID-19 patients.\n<\/p>\n<p>\nAccumulating evidence suggests that an increased level of inflammatory mediators, including cytokines, are associated with the severity of COVID-19.<sup>1<\/sup> Cytokine storm causes an overreaction of the immune system that can cause the body to attack its own tissues and organs, leading to a high proportion of deaths from COVID-19.\n<\/p>\n<p>\n\u201cMYMD-1\u2019s potential ability to stop one of the leading causes of death in COVID-19 is among the most exciting developments in our research to date,\u201d said Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD. \u201cMYMD-1 regulates the immuno-metabolic system by modulating numerous pro-inflammatory cell signaling molecules called cytokines. The primary cytokine that MYMD-1 inhibits is TNF-\u03b1 (tumor necrosis factor alpha). MYMD-1 has been shown in laboratory tests of human cells to block TNF-\u03b1 production \u2013 and the cytokine storm of COVID-19 that it produces \u2013 which have been implicated in causing injury and death from the coronavirus disease.\n<\/p>\n<p>\n\u201cMYMD-1 was first developed for the treatment of autoimmune and age-related diseases including extending human lifespan, but its mechanism of action offers potential therapeutic benefit for COVID-19 conditions,\u201d Dr. Chapman continued.\n<\/p>\n<p>\n\u201cAlong with our focus on extending healthy lifespan, treatment for COVID-19-related complications is now a cornerstone of our clinical development plan for MYMD-1.\u201d\n<\/p>\n<p><b>COVID-19 Associated Depression<\/b><\/p>\n<p>\nMYMD-1 may also be effective as a therapy for COVID-19-associated depression. MyMD is collaborating with a major medical school for a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression and cytokine elevation in patients affected with COVID-19. As a COVID-19-related therapy, MYMD-1 has the potential to move rapidly toward FDA approval through a special emergency program created to move new treatments into the clinic as quickly as possible.\n<\/p>\n<p>\nAccording to MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D., \u201cThe importance of our upcoming Phase 2 trial can\u2019t be overstated. Despite the prevalence of COVID-19-related mental illness, our trial will be the first clinical trial to date of a pharmaceutical intervention to treat COVID-19-related immune-mediated depression.\u201d\n<\/p>\n<p><b>Aging and Lifespan<\/b><\/p>\n<p>\nAs an immuno-metabolic regulator, MYMD-1 is being developed to target aging (such as sarcopenia and frailty) and depression in age or inflammatory-related diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic.\n<\/p>\n<p>\n\u201cWe are equally excited to launch a second Phase 2 trial of MYMD-1 in the near term,\u201d Dr. Chapman added. \u201cWith two Phase 2 trials in progress simultaneously, we are working to position ourselves to be able to commercialize and monetize two assets with very promising combined market value.\u201d\n<\/p>\n<p><b>About MyMD Pharmaceuticals, Inc.<\/b><\/p>\n<p>\nMyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage pharmaceutical company committed to extending healthy lifespan in humans by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\u03b1 and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-\u03b1 blocking drugs, and aging and longevity. The Company\u2019s second drug platform, Supera-CBD, is based on a novel synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.mymd.com%2F&amp;esheet=52472092&amp;newsitemid=20210805005659&amp;lan=en-US&amp;anchor=www.mymd.com&amp;index=2&amp;md5=9e10401ec23595ad5182e8132a70daf1\">www.mymd.com<\/a>.\n<\/p>\n<p><b>Cautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD\u2019s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD\u2019s pharmaceutical candidates; the timing and results of MyMD\u2019s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD\u2019s ability to retain and attract senior management and other key employees; MyMD\u2019s ability to quickly and effectively respond to new technological developments; MyMD\u2019s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD\u2019s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD\u2019s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, filed by MyMD on May 18, 2021. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n<p>\n__________________________\n<\/p>\n<p><sup>1<\/sup><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7527296%2F%23%3A%7E%3Atext%3DAccumulating%252520evidence%252520suggests%252520that%252520the%2Cchemoattractant%252520protein%25252D1%252520%2528MCP1%25253B&amp;esheet=52472092&amp;newsitemid=20210805005659&amp;lan=en-US&amp;anchor=National+Center+for+Biological+Information&amp;index=3&amp;md5=654b1d0a4897d820c14282cf73cd896a\">National Center for Biological Information<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210805005659\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210805005659\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Robert Schatz<br \/>\n<br \/>(646) 421-9523<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:rschatz@mymd.com\">rschatz@mymd.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mymd.com%2F&amp;esheet=52472092&amp;newsitemid=20210805005659&amp;lan=en-US&amp;anchor=www.mymd.com&amp;index=4&amp;md5=e9cbb97549dd18b604ef06921da81641\">www.mymd.com<br \/>\n<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Will Johnson<br \/>\n<br \/>201-465-8019<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:MYMD@antennagroup.com\">MYMD@antennagroup.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.antennagroup.com&amp;esheet=52472092&amp;newsitemid=20210805005659&amp;lan=en-US&amp;anchor=www.antennagroup.com&amp;index=5&amp;md5=2e694ebc494e262381474e22dd77a241\">www.antennagroup.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Maryland<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Stem Cells Biotechnology Health General Health Pharmaceutical Mental Health Other Science Research Infectious Diseases Science Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study MYMD-1 human cell research study demonstrates drug\u2019s ability to target immune dysfunction and cytokine storm that leads to death from COVID-19 Phase 2 trial of MYMD-1 as a therapy for COVID-19-associated depression and cytokine elevation expected to begin by fourth quarter 2021; initial trial data expected in first quarter 2022 BALTIMORE, Md.&#8211;(BUSINESS WIRE)&#8211;MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (\u201cMyMD\u201d or \u201cthe Company\u201d), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that a human cell research study of lead clinical compound MYMD-1 found the drug to be effective in suppressing the cytokine &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-524255","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study MYMD-1 human cell research study demonstrates drug\u2019s ability to target immune dysfunction and cytokine storm that leads to death from COVID-19 Phase 2 trial of MYMD-1 as a therapy for COVID-19-associated depression and cytokine elevation expected to begin by fourth quarter 2021; initial trial data expected in first quarter 2022 BALTIMORE, Md.&#8211;(BUSINESS WIRE)&#8211;MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (\u201cMyMD\u201d or \u201cthe Company\u201d), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that a human cell research study of lead clinical compound MYMD-1 found the drug to be effective in suppressing the cytokine &hellip; Continue reading &quot;MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-05T14:33:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study\",\"datePublished\":\"2021-08-05T14:33:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/\"},\"wordCount\":1093,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/\",\"name\":\"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-08-05T14:33:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/","og_locale":"en_US","og_type":"article","og_title":"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study - Market Newsdesk","og_description":"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study MYMD-1 human cell research study demonstrates drug\u2019s ability to target immune dysfunction and cytokine storm that leads to death from COVID-19 Phase 2 trial of MYMD-1 as a therapy for COVID-19-associated depression and cytokine elevation expected to begin by fourth quarter 2021; initial trial data expected in first quarter 2022 BALTIMORE, Md.&#8211;(BUSINESS WIRE)&#8211;MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (\u201cMyMD\u201d or \u201cthe Company\u201d), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that a human cell research study of lead clinical compound MYMD-1 found the drug to be effective in suppressing the cytokine &hellip; Continue reading \"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-05T14:33:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study","datePublished":"2021-08-05T14:33:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/"},"wordCount":1093,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/","name":"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-08-05T14:33:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210805005659r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-lead-compound-mymd-1-shown-to-suppress-a-major-cause-of-death-in-covid-19-in-human-cell-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MyMD Pharmaceuticals\u2019 Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/524255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=524255"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/524255\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=524255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=524255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=524255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}